This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Wada, S. Articles by Katayama, S. Search for Related Content PubMed PubMed Citation Articles by Wada, S. Articles by Katayama, S.

Regulation of Calcitonin Receptor by Glucocorticoid in Human Osteoclast-Like Cells Prepared in Vitro Using Receptor Activator of Nuclear Factor-B Ligand and Macrophage Colony-Stimulating Factor¹

Fourth Department of Internal Medicine, Saitama Medical School (S.W., S.Y., T.N., T.M., S.Ki., S.S., M.I., S.Ka.), Saitama 350-0495, Japan; and Department of Orthopedics and Trauma, University of Adelaide (D.M.F.), Adelaide, South Australia 5001, Australia

Address all correspondence and requests for reprints to: Seiki Wada, M.D., Fourth Department of Internal Medicine, Saitama Medical School, 38 Morohongo Moroyama-cho, Iruma-gun, Saitama 350-0495, Japan. E-mail: wadas{at}saitama-med.ac.jp

Using mouse osteoclast-like cells (OCs), we have shown that treatment with glucocorticoids (GCs) resulted in an increase in calcitonin (CT) binding by enhancing CT receptor (CTR) gene transcription. Additionally, treatment with GCs demonstrated increased sensitivity to CT. There is, however, scant information on the effects of GC or CTR regulation by GCs in human osteoclasts. In this study we examined CTR regulation by GCs and the effects of GCs and CT together in human OCs. OCs were prepared by treatment of peripheral blood mononuclear cells in vitro with soluble receptor activator of nuclear factor-B ligand and macrophage colony-stimulating factor. Treatment of mature OCs with dexamethasone (Dex) resulted in a dose- and time-dependent increase in [¹²⁵I]salmon CT (sCT) binding capacity. Treatment with Dex enhanced CTR messenger RNA (mRNA) expression, suggesting that CTR up-regulation is at least partly due to an increase in de novo CTR synthesis. Triamcinolone and prednisolone reproduced the Dex effect on [¹²⁵I]sCT-specific binding and CTR mRNA expression, but 17ß-estradiol, progesterone, dehydroepiandrosterone, and aldosterone did not. A Scatchard plot analysis showed that Dex enhanced CTR number with a minimal change in the affinity to sCT. Autoradiographic studies using [¹²⁵I]sCT showed that Dex enhanced the CTR density on individual multinuclear OCs. Up-regulation of [¹²⁵I]sCT-specific binding and CTR mRNA expression was seen even in the presence of sCT, but the enhancement diminished subsequently at later times (36–48 h after sCT removal), which was consistent with our previous observation in mouse OCs. This suggests that GCs and CTs act on CTR expression differently, consistent with our previous work using mouse OCs, in which we found that GCs increased transcription of CTR gene expression, whereas CT reduced CTR mRNA stability. The results obtained in this study show that GC increased CTR expression and sensitivity to CT in cells of the human osteoclast lineage and provide the basis for understanding the beneficial effects of combination treatment with GCs and CTs in malignancy-associated hypercalcemia.